203 related articles for article (PubMed ID: 15134628)
1. Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.
Reardon DA; Quinn JA; Rich JN; Gururangan S; Vredenburgh J; Sampson JH; Provenzale JM; Walker A; Badruddoja M; Tourt-Uhlig S; Herndon JE; Dowell JM; Affronti ML; Jackson S; Allen D; Ziegler K; Silverman S; Bohlin C; Friedman AH; Bigner DD; Friedman HS
Neuro Oncol; 2004 Apr; 6(2):134-44. PubMed ID: 15134628
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
Quinn JA; Reardon DA; Friedman AH; Rich JN; Sampson JH; Vredenburgh J; Gururangan S; Provenzale JM; Walker A; Schweitzer H; Bigner DD; Tourt-Uhlig S; Herndon JE; Affronti ML; Jackson S; Allen D; Ziegler K; Bohlin C; Lentz C; Friedman HS
Neuro Oncol; 2004 Apr; 6(2):145-53. PubMed ID: 15134629
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Vredenburgh J; Rich JN; Gururangan S; Badruddoja M; Herndon JE; Dowell JM; Friedman AH; Friedman HS
Cancer; 2005 Jan; 103(2):329-38. PubMed ID: 15558802
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
Turner CD; Gururangan S; Eastwood J; Bottom K; Watral M; Beason R; McLendon RE; Friedman AH; Tourt-Uhlig S; Miller LL; Friedman HS
Neuro Oncol; 2002 Apr; 4(2):102-8. PubMed ID: 11916501
[TBL] [Abstract][Full Text] [Related]
6. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
[TBL] [Abstract][Full Text] [Related]
7. Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts.
Castellino RC; Elion GB; Keir ST; Houghton PJ; Johnson SP; Bigner DD; Friedman HS
Cancer Chemother Pharmacol; 2000; 45(4):345-9. PubMed ID: 10755324
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Raizer JJ; Malkin MG; Kleber M; Abrey LE
Neuro Oncol; 2004 Jul; 6(3):247-52. PubMed ID: 15279717
[TBL] [Abstract][Full Text] [Related]
9. Irinotecan therapy in adults with recurrent or progressive malignant glioma.
Friedman HS; Petros WP; Friedman AH; Schaaf LJ; Kerby T; Lawyer J; Parry M; Houghton PJ; Lovell S; Rasheed K; Cloughsey T; Stewart ES; Colvin OM; Provenzale JM; McLendon RE; Bigner DD; Cokgor I; Haglund M; Rich J; Ashley D; Malczyn J; Elfring GL; Miller LL
J Clin Oncol; 1999 May; 17(5):1516-25. PubMed ID: 10334539
[TBL] [Abstract][Full Text] [Related]
10. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
Cloughesy TF; Filka E; Kuhn J; Nelson G; Kabbinavar F; Friedman H; Miller LL; Elfring GL
Cancer; 2003 May; 97(9 Suppl):2381-6. PubMed ID: 12712460
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.
Gururangan S; Cokgor L; Rich JN; Edwards S; Affronti ML; Quinn JA; Herndon JE; Provenzale JM; McLendon RE; Tourt-Uhlig S; Sampson JH; Stafford-Fox V; Zaknoen S; Early M; Friedman AH; Friedman HS
Neuro Oncol; 2001 Oct; 3(4):246-50. PubMed ID: 11584894
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Friedman HS; Pluda J; Quinn JA; Ewesuedo RB; Long L; Friedman AH; Cokgor I; Colvin OM; Haglund MM; Ashley DM; Rich JN; Sampson J; Pegg AE; Moschel RC; McLendon RE; Provenzale JM; Stewart ES; Tourt-Uhlig S; Garcia-Turner AM; Herndon JE; Bigner DD; Dolan ME
J Clin Oncol; 2000 Oct; 18(20):3522-8. PubMed ID: 11032594
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
Chang SM; Prados MD; Yung WK; Fine H; Junck L; Greenberg H; Robins HI; Mehta M; Fink KL; Jaeckle KA; Kuhn J; Hess K; Schold C
Cancer; 2004 Apr; 100(8):1712-6. PubMed ID: 15073861
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.
Quinn JA; Pluda J; Dolan ME; Delaney S; Kaplan R; Rich JN; Friedman AH; Reardon DA; Sampson JH; Colvin OM; Haglund MM; Pegg AE; Moschel RC; McLendon RE; Provenzale JM; Gururangan S; Tourt-Uhlig S; Herndon JE; Bigner DD; Friedman HS
J Clin Oncol; 2002 May; 20(9):2277-83. PubMed ID: 11980998
[TBL] [Abstract][Full Text] [Related]
15. CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma.
Chamberlain MC; Glantz MJ
J Neurooncol; 2008 Sep; 89(2):231-8. PubMed ID: 18480965
[TBL] [Abstract][Full Text] [Related]
16. The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
Friedman HS; Keir ST; Houghton PJ
Cancer; 2003 May; 97(9 Suppl):2359-62. PubMed ID: 12712457
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Gururangan S; Sampson JH; McLendon RE; Herndon JE; Friedman HS
Cancer; 2009 Jul; 115(13):2964-70. PubMed ID: 19402172
[TBL] [Abstract][Full Text] [Related]
18. Treatment of recurrent gliomas with 1,3-bis(2-chloroethyl)-1-nitrosourea and alpha-difluoromethylornithine.
Prados M; Rodriguez L; Chamberlain M; Silver P; Levin V
Neurosurgery; 1989 Jun; 24(6):806-9. PubMed ID: 2546093
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma.
Rajkumar SV; Buckner JC; Schomberg PJ; Reid JM; Bagniewski PJ; Ames MM; Cascino TL; Marks RS
Int J Radiat Oncol Biol Phys; 1998 Dec; 42(5):969-75. PubMed ID: 9869217
[TBL] [Abstract][Full Text] [Related]
20. Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study.
Hochberg F; Prados M; Russell C; Weissman D; Evans R; Cook P; Burton G; Eisenberg PD; Valenzuela R; Verkh L
J Neurooncol; 1997 Mar; 32(1):45-55. PubMed ID: 9049862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
